Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.

doi:10.1186/s12885-022-09828-2

Back to search

Article

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.

BMC cancer - 9 Jul 2022

Lu Hao, Weng Xiang-Qin, Sheng Yan, Wu Jing, Xi Hui-Min, Cai Xun

Abstract excerpt

BACKGROUND: Midostaurin combined with chemotherapy is currently used to treat newly diagnosed acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 (FLT3)-mutations. However, midostaurin acts as an antagonist to some chemotherapeutic agents in leukemia cell lines without FLT3 muta...

Topics

Animals
Humans
Leukemia, Myeloid, Acute
Mice
Mitogen-Activated Protein Kinase Kinases
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-akt
Staurosporine
Tretinoin
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.